Greetings, and welcome to the Align Technology First Quarter 2018 Earnings Conference Call. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Shirley Stacy. Please go ahead.

Good afternoon. Thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued first quarter 2018 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Note that, beginning in Q1 2018, the American region now includes the U.S., Canada and Latin America. Previously, Latin America was combined with the EMEA results for reporting purposes and included in the international total. While the Latin America region has been relatively immaterial to Align's overall results, we've adjusted our prior-period regional breakouts to reflect this change so our year-over-year comps are consistent. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 PM Eastern Time through 5:30 PM Eastern Time on May 9. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13678038 followed by pound. International callers should dial 201-612-7415 with the same conference number. As a reminder, the information that the presenters will discuss today will include forward-looking statements including statements about Align's future events, product outlook and the expected financial results for the second quarter of 2018. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We've posted historical financial statements, including the corresponding reconciliations and our first quarter conference call slides, on our website under Quarterly Results. Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights in the quarter and briefly discuss the performance of our two operating segments, clear aligners and scanners. John will provide more detail on our financial results and discuss our outlook for the second quarter. Following that, I'll come back and summarize a few key points and open up the call to questions. I'm pleased to report better-than-expected first quarter results and a strong start to the year for Align with the revenue – with revenues, volumes and EPS above guidance. Record Q1 revenues were up 41% year-over-year, reflecting continued strong Invisalign volume across all geographies and customer channels, as well as iTero scanner sales which are up over 84% year-over-year. Q1 Invisalign volume growth of 31% year-over-year was driven by increased utilization, including strong teen case growth globally and expansion of our customer base, which included over 4,200 new Invisalign-trained doctors worldwide. Turning to specifics around our first quarter results. Let's start with results of our Americas region. For the Americas, Q1 was a good quarter with Invisalign volume up 7.1% sequentially and 24% year-over-year, reflecting growth in both our Orthodontist and GP Dentist channels. In Q1, we trained 1,600 new Invisalign doctors in the Americas region, of which 455 were in Brazil alone. We're also seeing a continued ramp-up for Invisalign treatment. For the Americas region, year-over-year growth was led by Ortho customers with another record quarter for North America Ortho utilization of 15.3 cases per doctor. Q1 Invisalign utilization for our North American GP Dentist were also up year-over-year, although modestly and predominantly reflecting continued expansion of the GP customer base, which included 900 from new North American GPs who submitted Invisalign cases for the first time this quarter. During the…

Thanks, Joe. Now, for our Q1 financial results. Total company revenue for the first quarter was a record $436.9 million, up 3.7% from the prior quarter and up 40.8% from the corresponding quarter a year ago. Year-over-year revenue growth includes a five point benefit from favorable foreign exchange. Clear aligner revenue of $385.5 million was up 5.8% sequentially on higher than expected volume. Year-over-year clear aligner revenue growth of 36.5% reflected strong Invisalign shipment growth across all customer channels and geographies and increased Invisalign ASPs. Q1 Invisalign ASPs were up sequentially approximately $5 from Q4 to $1,310, reflecting favorable foreign exchange and product mix, partially offset by sales promotions and revenue deferrals. On a year-over-year basis, Q1 Invisalign ASPs were up approximately $40, reflecting favorable foreign exchange, price increases and product mix partially offset by sales promotions and deferrals related to additional aligners. For the first quarter, total Invisalign shipments of 272,200 cases were up 6.7% sequentially and up 30.8% year-over-year, driven by growth across all regions. For Americas' Orthodontists, Q1 Invisalign case volume was up 8.5% sequentially and up 27% year-over-year. For Americas' GP Dentists, Invisalign case volume was up 5.1% sequentially and up 19.6% year-over-year. For international doctors, Invisalign case volume was up 6.2% sequentially and up 43.4% year-over-year. Our scanner and services revenue for the first quarter was $54.4 million, down 10% sequentially due to the lower volume from the Q4 seasonality effect and up 84% year-over-year, primarily due to higher volume partially offset by lower ASPs due to promotions and discounts. Moving on to gross margin. First quarter overall gross margin was 74.9%, down 0.6 points sequentially and down 1 point year-over-year. Clear aligner gross margin for the first quarter was 77%, down 0.6 points sequentially primarily due to increased aligners per case and higher training…

Thanks, John, and thanks to those for joining the call today. I'm pleased with our start to 2018 as well as our continued progress and execution of our strategic growth drivers. There are a lot of changes happening in Dentistry and Orthodontics today. But the industry remains healthy and I think customers are starting to see new opportunities for how they treat patients and reach new customers. We're looking forward to an exciting and productive AAO Meeting in Washington, D.C. where we'll get to showcase our new products on the scanner side and also with Invisalign First. We're also going to have a pop up version of our Invisalign pilot store as a way to answer customer questions and to get their perspective on our program. Then, we'll be in Singapore at the end of May, hosting our third Asia-Pacific Summit. We will be expecting about 1,000 delegates from across the region attending a two-day peer-to-peer education event. We've got a lot going on in Q2 and I look forward to sharing more with you at our upcoming financial conference at our Investor Day in New York on May 23. Thinking about Monday for sure. On May 23. With that, I'll turn it over to the operator, and we'll open up to your questions. Thank you.

Thank you. Our first question comes from Robert Jones of Goldman Sachs. Please proceed with your question. Robert Patrick Jones - Goldman Sachs & Co. LLC: Great. Thanks guys for the question. Joe, just looking at the expected new revenue growth rate for the year, you know now above the long-term model. I'm sure it's a combination of several factors, but I was hoping maybe you could just maybe in ranked order attribute what really has gone better than expected so early in the year, if we think about teen off to a good start on the new product launches. Obviously, iTero seems to be pacing much better than certainly we were expecting. Could you maybe just give us some insight into what out of the gate this year has gone better than planned?

Well, we had an aggressive plan for the year. But to start off, Bob, I'd say, if you look at the international business, it continues to be very strong with APAC and EMEA, really good performance in the Americas particularly around North America, too. We started to segment it. You mentioned it. Our teen product is up pretty substantially that way. iTero sales have been terrific in that sense. We talked about how customers more and more are recognizing that whole digital workflow and how important it is. And you can see with our scanning now North American being close to 67%, that's just really working out well. And we know when they purchase iTero scanner, we see more Invisalign sales. Lastly, I'd say our segmentation – I mentioned it in my script too, is the segmentation of GP and Ortho very specifically and also segmenting consumers in the sense of our Concierge service and how more and more we target consumers and lead them into specific docs from a Doc Locator standpoint. And that's gone a little better than expected too. So, overall, the company has been executing well across geographies and across our segmentation and product plans. Robert Patrick Jones - Goldman Sachs & Co. LLC: Great. And I appreciate that. And then, it looks like you're seeing some early traction already from Invisalign First. I was wondering if maybe you could share with us how that launch of a product like that changes the addressable market that you can actually go after. Just getting some thoughts from you would be helpful around how much more expanded that the younger market becomes with a product like First?

Yeah. First of all, those 600 cases we did, that product launches in July. Those were actually just cases we put in place from a clinical study standpoint to prove the whole thing. So, really, that 600 is – I mean, you're going to see us do more and more clinical work like that to do a lot of cases, Bob, just to make sure that we have good evidence for our customer bases we go out there to work on. Secondly, when you look at the teen marketplace, palatal expansion, or what we call Phase 1 represents about 20% of the marketplace. Now, this is dental expansion. It's not morphology or bone expansion like you have in rapid palatal expansion. So, in the past, we said we've roughly can do 60% to 65% of the cases with Invisalign. What Invisalign First dental expansion does is expand that that market served opportunity another 10%. And then, we'll follow that with a rapid palatal expander that we're currently going through now, and that will increase it another 10%, too, so we can cover that whole 20% Phase 1 part that you have with teens out there. And that also has a good entree for us because often it's Phase 1, Phase 2 treatments were teens or young children that are 7 to 8 age have the palate expansion play and then it goes on to dental kind of work from an orthodontic standpoint later on in their teens. And so, there's a good transition period for that, too. So it's a great product. It's targeting that segment of the marketplace that we haven't had technology at before and it's specifically an orthodontic product that we've developed here. Robert Patrick Jones - Goldman Sachs & Co. LLC: Awesome. Great. Thanks for the questions.

All right, Bob. Thanks.

Our next question comes from Brandon Couillard of Jefferies. Please proceed with your question.

Thanks. Good afternoon. Joe, to the extent you're comfortable, I would love to just hear your view on kind of what the path forward is with respect to SDC, SmileDirect. And then, John, any chance you could share with us the percent of cases that you manufactured for them in the first quarter?

We can't really get into specifics. And obviously, we're going through litigation, we have to work through litigation. I'll just say we continue to have a good relationship with David and his team, and we just have a disagreement in the sense of obviously the contract that we're in and we're going to work through this from a litigation standpoint, so as that develops, we'll be able to be more clear with you as to what's going on.

Fair enough. And then, one more. Joe, with respect to the Invisalign store model, would be curious to hear your views on how that's tracking relative to plans. It looks like you pulled forward perhaps by a couple of quarters the East Coast build outs. What are some of the things you're learning and what have you learned so far from the initial experience?

Brandon, first of all, we didn't pull those forward. That was in our plan as we had for 2018 and we're just sequentially putting them in. And we've learned – honestly, these stores, we've learned a lot in the sense and these – what we learn helps our doctors an awful lot too about how you take a basic consumer and you turn them into a patient. We learned that visualization is really important. The speed of that visualization, I mean, you scan, you can show a patient what their teeth are going to look like with certain kind of treatment options, gives them a lot of confidence then to go to a doctor and to see a doctor and to complete that treatment piece. We've learned a lot about our software too in the sense of how it has to respond from a patient standpoint. There's also a lot that we're doing from a marketing standpoint in the sense of turning interest from a consumer over to a store and then back to a doc. In other words, turning consumers into patients also. Through all that, I'll tell you the iTero scanner again is really critical in being able to do this. It's really the key on the visualization piece. But also, our treatment software planning in the sense of making it as real time as possible, so patients can see how their teeth will move and what their smile will look like. Those combinations become really important, not just in the store, but as we translate that software to our doctor partners.

Very good. Thank you.

Thanks, Brandon. Next question, please.

Yeah.

Our next question comes from John Kreger of William Blair. Please proceed with your question. John C. Kreger - William Blair & Co. LLC: Hi. Thanks very much. Joe, can you give us a sense in terms of the feedback that you're hearing from your field sales force on the competitive front? Are you seeing any changes perhaps in promotional activity or pricing from competitors at least at the low end?

No, we haven't seen any change at all, John. I mean, we – I mean, the same cast of competitors are still out there that we had before. Obviously, we expect the 3M product at the AAO. We are pretty sure to see one there. We saw the supply announcement at the MTM expansion in the 510(k) that they've done. But we haven't seen that translated to any kind of strategy or implementation in the marketplace yet. We expect to see that in the second half. Our guess, John, is pretty much what we've been telling you and the rest of the teams over the last couple years is, we expect this to be midrange products. So in the 26 aligner or less kind of an area, we expected kind of a slow ramp up just because of the nature of how you have to scale in this business takes some time in treatment planning and also manufacturing. So I mean, you can see with our kind of bullish forecast for the second half of the year that John just called. We pretty much had this in place in the sense of what we thought we would face and we haven't really changed that analysis since we put the plan together last year. John C. Kreger - William Blair & Co. LLC: Great. Thanks. And one quick follow-up on the scanner business. Did you see any kind of stocking by Patterson in the U.S. that might cause sales to slow as we move through this year or do you view that as end demand tracking as well as it would appear?

No stocking here. In demand, that's a policy we have here. John C. Kreger - William Blair & Co. LLC: All right. Great. Thank you.

Our next question comes from Erin Wright of Credit Suisse. Please proceed with your question. Erin Wilson Wright - Credit Suisse Securities (USA) LLC: Great. Thanks. Can you speak to the more recent financing pilot, I guess any surprises with that sort of initiative and when that would be a more meaningful contributor to growth?

Yeah. This is John. The pilot that we have is – took place in end of fourth quarter and through the first quarter, we saw great results. And it is going wider across the U.S. starting this quarter, where customers now – customers and ultimately the patients have a lot more flexibility in terms of how they want to finance and work through different financing options that they might have. Erin Wilson Wright - Credit Suisse Securities (USA) LLC: Okay. I'll follow-up later there and then on – can you speak I guess on China and opportunity there I guess as well as the competitive landscape not just maybe from the clear aligner segment but also the broader iTero opportunity with the launch announced today? Thanks.

I think – it's Dr. Joe Hogan. We're excited about that. I mean, our growth in China, China is our second largest market, our growth over there has been tremendous. It's hard to believe that right now everything we do in China is basically PVC impression. So and I mentioned in my script about 2% penetration of intraoral scanners in China. So from a competitive standpoint, our market is wide open in this sense and you could see that from those kind of – now we have to sell, we have to train, there's a lot of things we learned in Japan, because the iTero scanner being approved in Japan last year in the sense of how you have to ramp up and a lot of technology and people to bring our customers up to speed and saw that friction we are anticipating for this year as we ramp up in China, we're putting people in place and training in place, to be able to get that done. Erin Wilson Wright - Credit Suisse Securities (USA) LLC: Okay, great. Thank you.

Yeah. Thank you.

Our next question comes from Matt O'Brien of Piper Jaffray. Please proceed with your question. Kevin M. Farshchi - Piper Jaffray & Co.: Hi, guys. Thanks for taking the question. This is Kevin, on for Matt today. I wanted to start with the mandibular advancement ramp abroad, kind of what's most driving that strength. I've heard about it being incredible for the last two quarters. And then secondly with that assuming approval here in the U.S., how fast exactly is the U.S. ramp? Is this something that Ortho customers have been asking for a long time? Thank you.

Hey, Kevin. It's Joe. First of all, I'd say from a math standpoint, the ramp overseas, this is just a product that's unique. You obviously address mandibular issues and these are people, teens that are between the ages of 10 and 12 usually with that bone development through a jaw standpoint. And there's really nothing in the world to tell you have twin block and things like this, that's looks like a torture device basically with metal that's used to move kids forward with also composites. What this does is it moves your jaw forward with removable aligners and also straightens your teeth at the same time. So it's a true breakthrough for that end of the market and I think that's why you see really good pickup. Secondly is all of these products as it moves in the United States, I wouldn't model some kind of huge increase in teens because of mandibular advancement in the United States, because there is always a slow takeoff of this because orthodontist want to try it, they want to see success with their patients, they build that kind of credibility to the product line, they continue to move on. So from a North America standpoint, this is more of a 2019 discussion with math in the sense of maybe significant kinds of opportunities than I would say in the second half of this year Kevin M. Farshchi - Piper Jaffray & Co.: Okay. Thanks, Joe. That's really helpful. I just had one follow up on a previous question on the competitive front and then additionally with the DTC effort. I was just curious are you hearing from your customers specifically becoming increasingly aware of the additional offerings in your view? And secondly, are they pushing back a little bit on pricing and looking for better discounts and things like this as a result of the DTC effort increasing and then also kind of layering on new products in the next coming years?

Kevin, I'd say look there's increasing awareness because I mean, it's mainly SDC in North America has really extensive advertising and so it's hard to watch TV and not run into in Invisalign ad or an SDC ad in that sense. But I wouldn't say, our customers always want lower prices like almost any other customers in the world, and anything else to sell. So I wouldn't say that the SDC price range has created more sensitivity with our orthodontic and GP customers out there. I will say that there is a price elasticity curve and obviously that kind of lower very I'd say minor type of tooth movement kind of things that opens up a new segment in the marketplace that frankly hasn't been serviced in a big way before. And so I think it just makes doctors aware of the more of a segmentation in the market of not doing a full bite correction, but just doing maybe your social six or just correcting a smile that someone is not comfortable with, that's a new segment in the market. It's priced in a different way and I'd say that's not a pushback on us on price it's more of a look at how to service those patients or what's the best products to do that with. Kevin M. Farshchi - Piper Jaffray & Co.: Okay, perfect. Thanks so much.

Our next question comes from Steve Beuchaw of Morgan Stanley. Please proceed with your question. Steve Beuchaw - Morgan Stanley & Co. LLC: A it's new one. Hey thanks for taking the questions.

Hey Steve.

Hey, Steve. Steve, your friends are here at... Steve Beuchaw - Morgan Stanley & Co. LLC: Yeah. Hi. Good to talk to you. The GP number in the quarter kind of sticks out in a really good way, really on a tougher comp kind of influx. Is it something going on in GP in the U.S. I mean, we don't have you know I go out in the field, what was the magic there?

You know I don't – you know, it's not magic and it's not a surprise Steve I'd say. First of all SDO – I mean the DSO marketplace has been big for us right. So you know our work with Hartman, what's going on there and some other dental service organizations, team in North America has been very good at executing around those opportunities. Secondly, honestly, the increased advertising that that we've been doing, okay, has an overall halo effect with driving patients to GPs asking for Invisalign treatment. And we've noticed that since last year and we started cranking up advertising, so that is a kind of a residual effect or a second order effect that help the GPPs. Thirdly, Steve is we're doing more and more segmentation on salespeople, calling on GPs in a GP kind of a way. In other words, understanding GP workflows, they don't want to be orthodontists, having products like you know that are more simple for them to use in the sense of utilizing that within the workflow of a normal restorative kind of a dentistry type of workflow. So those three areas are doing primarily. Steve Beuchaw - Morgan Stanley & Co. LLC: Yeah. Super helpful. Thanks for that. And then you guys, you may have set a new record for press releases in one afternoon. I mean you introduced a lot of new stuff today and we could spend a lot of time on any one of them. But I wonder if there's any way to give us as a sort of high level of view Joe and what you think these products mean for the growth profile of the company over the next two years, the sum total of getting iTero into China and getting the GP channel you know a little bit more automated, getting more cameras on the market. What does this mean for the next two years or three years? Thanks so much.

Steve, first I'd be completely honest with you too. We're still learning, right. I mean, if you remember like a year ago, we weren't – we wouldn't really be tied down to tell you that we sell more iTero than we sell more aligners. Today I'd tell you a very concretely because we have enough data today that we sell more iTeros, we sell more aligners. We're gaining a lot of confidence in APAC as we continue to grow, like I mentioned on a previous question is in Japan, we learned a lot about what iTero can do, as you start to ramp up in a new market like Asia. Now, Japan is completely different than China has been completely how you do business there, but we do – we know how to go in there and we can anticipate in a sense of what China will need in the kind of uptake we'll have with those kind of scanners. So the iTero's that we just announced the two products in iTero, remember this is the equipment business. I grew up in equipment business and medical, that these are platforms, right these are new platforms that we're moving forward on that help to extend what we already know in that sense. So like the flex product allows you to put it into a compatible computer, move it around the different offices, that's what our customers are basically asking for, it's sort of break – new breakthrough in scanner technology is an extension. You're going to see us continue to do that as we work off a successful platform that allows us not to just go wider from a geographical standpoint like China, but to go deeper in a sense of the workflow and what our orthodontists and our GPs really…

Yeah. All right.

Our next question comes from Ravi Misra of Berenberg Capital Markets. Please proceed with your question.

Hi. I appreciate taking the call. A couple of questions. One on the store pilot, just kind of trying to get a sense for what the revenue potential that you see out of that is in the long-term? It sounds like you're having us moderate some of our expectations here based on what the contribution could be from SmileDirect itself as you guys work through you know your negotiations with them; and if you could give us some information on that, that would be great? And then secondly, maybe just a housekeeping question just on the EPS line, the 5 points of currency. What was the flow through down to the bottom line on that? Thank you.

John, I'll take that last one.

Yeah. I'll take that first on Ravi on the EPS, you know, so 5 points on revenue and – we are – our model works as you know usually we get about 3 times the benefit on revenue as it is to profitability.

So, Ravi, on the store pilot, we were not going to share any data on the store pilot right now. We call them pilots for a reason, because we're learning and we're growing through that learning and you know it just becomes more understandable because we have more data points, but we'd be happy to share that with you. As far as the SDC and all, we haven't shared specifically what we expect from quarter-to-quarter. I have never wanted you to really evaluate Align stock on SDCs, we sell the SDC never wanted to do that. And so when you say, we're kind of moderating your views of volume I would say, we're talking lower 30% for this year, that's not a moderation in this sense of what we think the growth is. We just want you to not try to handicap that with SDC volume. This is our inherent volume that we're generating in this business.

Yeah and I think that's pretty clear given your case start by guidance in the low 30s now. So I appreciate that. And then finally, just on the reapportionment of the Latin American sales, can you just talk about whether that's going to – is that just a reporting issue or are you going to be realigning some of the business units internally as well with that? Thanks.

No, I mean what that does Ravi is, we have a regional strategy here, right. We have APAC from an Asia standpoint, we have EMEA from Europe. We've always had just North American organization, it's been kind of Latin America was reporting into another part of the organization. And so this just straightens out our organizational intention of having regions in each one of the three key areas. And – but frankly, and then we bought up our distributorships in those areas, in Latin America, and also Brazil and we're moving forward in those areas. So you saw many doctors retrained in Brazil alone. These are good opportunities for us and it allows us to focus on it in a more of a regional sense and be able to transfer best practices within the Americas throughout the organization. So it's just a – it's a move it's in line with our regional structure.

Great. Thank you very much.

Yeah. You're welcome.

Our next question comes from Jon Block of Stifel. Please proceed with your question.

Hey Jon. Jonathan David Block - Stifel, Nicolaus & Co., Inc.: Hey, Joe. Thanks for taking the question. So maybe two, the first one just the – on the new – iGo sort of iTero offering, is there a price point on that product, I didn't see it in the release and you know clearly you don't seem overly concerned with competition, but with that new iGo, iTero offering, I believe it's up to 20 stages. Joe is that sort of the part of the market that you do view as most susceptible and a competition does come in the next couple of weeks where they're going to try to crack the code a bit? And then I've got a follow-up. Thanks.

John you know this well and your analysis is right, if you take 15 up to 26, I mean that's been kind of a vacancy in the product portfolio for years. And so iGo wasn't derived without an understanding of that okay. Yeah, we do – I wouldn't call that – you know when you – if you really stand back from this, trying to do a full case with all the complexity it has to do with full cases. If you were a competitor coming in here, it's a very difficult thing to do. You want to kind of gradually learn and ramp up to that. So the logical, our logical conclusion is, yeah I mean, we're probably going to see more competition in the below 30 area. The good thing about that John, that's not new to us. We've seen competition from MTM and Angel Align and you can go down the list of competitors we've seen globally, ClearCorrect or whatever in that specific area. But when you look at Maui when you look at iGo, Maui was the structure we put in place or whatever. It just gives us more flexibility for our customers to be able to offer these products up and down the range than what we've had before. So yeah, could we respond better to competition? Yes. Is that an area we think they'll come in? Yeah, but we've already seen that and this is just a continuation of how we've been working with our customers and how we structure our product portfolio. Jonathan David Block - Stifel, Nicolaus & Co., Inc.: Okay. Great. I appreciate you read the reports Joe, I just need others do as well. Just to pivot for a moment, the scanners and driving utilization in the U.S., that's clearly played a big role over the past several years and we're seeing the scanners playing a bigger role globally, and you mentioned just starting to get into China. When you take a step back, is there any reason why the utilization step up which you now seem much more comfortable sort of verifying. That utilization step up would be any different globally especially someplace like China or Japan versus what we've seen in North America. In other words when we look out two years or three years from now, could that be sort of the next leg of growth in some of these more emerging markets? Thanks, guys.

Answer to that question is just a flat out, yes. I mean I don't think it's going to be any different in China. It hasn't been different Japan. We saw an uptake with the customers that took the initial iTeros there at John significantly. So we expect China to be the same way and other countries too. You know in Brazil, I think we've been successful with iTero in Brazil also. So yeah, that is another component of growth in the company overall. What's great is it's synergistic growth, right. You have equipment growth, but it really leads to the growth of our core product line which is Invisalign.

Our next question comes from Richard Newitter of Leerink Partners. Please proceed with your question.

Hi. Thanks for taking the questions. Just the first one, on the tax rate, so 13% for 2Q. Just wondering what should we be modeling for the full year?

The guidance that we had given for total year was, earlier on was 18%, so 18% in total would be what you should use, Richard.

Okay, so that's unchanged. And then Joe, just going back to the question I was asked earlier on competition and how if at all, it's factored into your outlook. I guess just can you comment on more specifically how you contemplated the impact of any incremental competition on your prior outlook. And I appreciate you revised your outlook upward and that's a bullish signal. But compare the current factoring of competition compared to kind of how you thought about it previously and if you could get a specific as possible, is it price, is it maybe just a little less utilization you otherwise would have felt comfortable providing to The Street just how are you thinking about that in quantifying it?

Hasn't changed for a year, honestly I mean, you can tell what we initiated during the beginning of the year we didn't think we'd have any really major competitive plays in that sense. We knew we'd see more competition, but we basically looked at our business and with the momentum of the business and projected that forward and you're seeing it within our numbers, there's no specificity that I want to share in the sense of what we think and how much in ASP and what areas. Just take a look at our bullish forecast going forward and as competition becomes more visible to us and more in line, we'll share with you what we're seeing and how we look at the business.

And a similar follow up to that line of questioning. Anything baked into your outlook specifically for mandibular contributing in the back half. I know you expect approval, but is there anything baked in for actual contribution to revenue and same on iTero. It feels like that came – the approval in China came a little bit ahead of plan I thought you had been talking about a second half kind of ramp for that and approval for that, was that a little earlier than expected?

First of all on MAF, no I wouldn't plan on anything from a – that would be material on MAF as I mentioned and the other thing for North America when we finally get it approved. On China, we were happy to move that through. We've had good work with our Chinese partners over there to move it through. Right now, we're not calling any upside on that I mean, as we indicated, we've had good iTero growth. We think that'll continue as we – it's not just about how fast you can sell iTero in China, there's a lot of infrastructure work you have to put in place as far as training and putting things in place to be able to sell through China from an infrastructure standpoint. So what's great about that is, we can kind of get a quarter up on that as if it would have been the second half of the year then we wouldn't have as much opportunity to be able to move that product.

Thank you.

You're welcome.

Our next question comes from Steven Valiquette of Barclays. Please proceed with your question.

Okay, great. Good afternoon, Joe and John. Thanks for taking the question. I guess for us just one or two quick follow-ups here on the addressable market. First probably an easy one but just to make sure to clarify here, when we're talking about this 20% of untapped orthodontic case starts you can now treat with Invisalign First. That 20%, that is within the prior industry view of roughly 10 million worldwide annual orthodontic case starts. Is that correct?

Steve, first of all, it's not 20%, okay? Invisalign First is about 10% because that's dental expansion, which means you're just really taking the teeth and rounding the arch, right? Rapid palatal expansion moves the bone, moves the palate, mouth. So, 10% more of the market would be Invisalign First, another 10% would be for rapid palatal expansion.

Hey, Steve, you're talking 20% of cases are related to Phase 1, and that's correct.

That's right.

What Joe is explaining is you're talking about TAM, right?

Correct. Yeah. More on the TAM that's correct. And really, I mean the more important question I wanted to get to at the end of the day really was that when we think about the 10 million worldwide orthodontic case starts TAM. I guess my real more critical question here is once Invisalign First is generally available and also once you do have U.S. approval for mandibular advance. And I'm just curious where we would stand after those events just on the approximate percent of that 10 million worldwide orthodontic case starts. Do you think you could treat right now overall with the overall Invisalign product profile and approval, that's really the more important question I wanted to ask.

I think the simple one on that Steve is it – before Invisalign First, we said 60%. Invisalign First takes us to 70%. Once we get rapid palatal expansion, it takes us to 80%. And that's the $10 million case starts that are out there, though that's based on 25% adult and 75% being teens. So, if you really want to nail that number, you're going to have to take 75% of 10 times 0.8.

Okay. All right. Okay. Thanks.

Yes.

Our final question comes from Jeff Johnson of Robert W. Baird. Please proceed with your question. Jeff D. Johnson - Robert W. Baird & Co., Inc.: Thank you. Good evening, guys.

Hey, Jeff. Jeff D. Johnson - Robert W. Baird & Co., Inc.: Hey, Joe. Let me go after the competition question maybe one other way here, I think we're all trying to circle around different things. But you guys are launching obviously a ton of stuff right now with the iGo in the Phase 1 and iTero expansion all that stuff. What's your view in the second half here, you guys expand the market quite a bit. And so, competition gets some share, but you guys are expanding markets so fast that you can put up that solid or that very strong second half guidance that seems to be implied there now or do you just really think competition doesn't get much traction? You know your comps get tougher in that so it's getting a little messy to try to figure out kind of how much of this is market expansion? How much may be competition, is this or isn't having an impact? But just conceptually how do you think it plays out that way?

Jeff, I think the best way to look at this is, don't look at this as binary. Competition comes in and just takes our share. We actually think that competition to a certain extent will less share because it'll give more legitimacy to clear aligners. And so, possibly in that lower segment of the marketplace could we lose some share? Sure. Sure, we could. At the same time we're expanding on the upper end with our product lines that you just saw with obviously mandibular advancement team, iGo in those areas. Jeff, the other side of this too is it's we've been saying this for a long time, it's hard to do this. I mean treatment planning facilities, making sure that you can ship aligners and actually ship them in sequence. So first, second, third are really first, second, and third aligners. Putting a sales team out there that they really can walk through customers and hold their hand in sensor, but it takes time to do this. It's not – this is not like a patent cliff we've been saying all along with something is a you know a biosimilar and you can put it in your portfolio and sell it the next day it's not like that. It will take time to ramp your competition. Jeff D. Johnson - Robert W. Baird & Co., Inc.: Yeah. Now that makes sense and then one last question for me just iTero anything qualitatively you can talk about maybe scanner sales in the U.S. and are you seeing any traction outside of Invisalign cases with iTero on any kind of restorative procedures anything like that just kind of trying to get to what is the mindset of the U.S. dentist right now are they are they willing or are they at the point where they want to use scanners for things you know obviously for Invisalign but for other things as well just what your view there that would be helpful?

Yeah. I mean, if you look at – I mean if you look at the three shape in us right, I mean three shape has a good position with GPs in a sense of restorative workflow and with the labs and whatever and you know they've helped to from a GP standpoint to grow the marketplace. We're the same way. We have a good restorative scanner. We have a great scanner from overall Invisalign standpoint and in both of us kind of raised the awareness and capability out in the marketplace. So, you know honestly, when you look at this thing Jeff long-term, this is – you're going to have a scanner you know one way or another your workflow is going to be digital going forward in dentistry. It starts around these kind of application restorative you know versus you know aligners and those kind of things. It'll flow through for the rest, so I don't know what you're thinking of in the sense of how to model that Jeff or what it means, but it just shows you more and more that this isn't just an for orthodontist. This is and we're developing a scanner that's brought across the marketplace to be one of the function well for GP and restorative, if you go back to iTero beginning right, it was function well for a GP and restorative. If we go back to iTero's beginning right, it was restorative scanner. When we bought that business, we're primarily was in G you know the general dentistry segment that it was developed around. But so I think I reported that we had 2.5 million restoratives scans done on iTero. So when our team is out there are calling on a GP, we're talking about not just that you can do our liners with this, I'm confident you can do this is a great very accurate restorative scanner that can communicate very well with your dental lab, that's really important in that net workflow. Jeff D. Johnson - Robert W. Baird & Co., Inc.: And scanner sales growing in the U.S. still, is there still a good market there for you guys on the scanner side?

And no question. Jeff D. Johnson - Robert W. Baird & Co., Inc.: Yeah. Thanks guys.

Hey. You saw the results of the iTero scanner business. You know the vast majority of the business is still in North America. Jeff D. Johnson - Robert W. Baird & Co., Inc.: Yeah. Just with the Japan approval and moving Brazil where you did into the Americas and I just wanted to check on that. So thanks.

All right.

Okay.

Well, thank you, everyone. This concludes our conference call for today. I want to remind everyone that we will be hosting our Investor Day at the Park Central Hotel in New York City on May 23. You can find more information and register directly on our Investor Relations webpage. Hotel rooms and group locker are limited and the cutoff to make your reservation is April 30. We hope to see you all there. Do you have any questions, please let us know.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.